Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company Complix N.V.
DescriptionAnti-IL-23 alphabody
Molecular Target Interleukin-23 (IL-23)
Mechanism of Action 
Therapeutic ModalityBiologic: Protein
Latest Stage of DevelopmentPreclinical
Standard Indication Autoimmune (unspecified)
Indication DetailsTreat autoimmune diseases and inflammation
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today